⌕
Freenome · FRNM · Nasdaq
Tenet — · insufficient data
Compare
$10.09−3.07%At close
$10.09−0.32 (−3.07%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Freenome (FRNM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Defense WorldNov 11, 2026 · 01:15 ET
Freenome (NASDAQ:FRNM) Stock Has Average Target Price of $18.00 According to Analysts

Shares of Freenome (NASDAQ: FRNM - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research ana…

● MarketBeatNov 10, 2026 · 21:16 ET
Freenome Q3 Earnings Call Highlights

Freenome NASDAQ: FRNM reported third-quarter revenue of $183.5 million, driven largely by revenue recognition following the U.S. Food and Drug Administration's approval of its blood-based colorectal cancer screening test…

● GlobeNewsWireNov 10, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Freenome Reports Third Quarter 2026 Financial Results

– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC –…

● GlobeNewsWireOct 20, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option

– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and …

● GlobeNewsWireOct 15, 2026 · 16:29 ETCOMPANY'S OWN WORDS
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026

BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to release its financial…

● Globe News WireOct 11, 2026 · 13:00 ET
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

- Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention - - Overall detection of colorectal cancer remaine…

● Seeking AlphaSep 22, 2026 · 12:24 ET
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition

Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a patient-friendly, bl…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just FRNM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.